Astrazeneca (AZN) Shares Outstanding (Weighted Average) (2016 - 2025)
Astrazeneca has reported Shares Outstanding (Weighted Average) over the past 11 years, most recently at $388.0 million for Q4 2025.
- Quarterly results put Shares Outstanding (Weighted Average) at $388.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $388.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $388.0 million, changed 0.0%.
- Shares Outstanding (Weighted Average) for Q4 2025 was $388.0 million at Astrazeneca, roughly flat from $388.0 million in the prior quarter.
- Over the last five years, Shares Outstanding (Weighted Average) for AZN hit a ceiling of $388.0 million in Q4 2023 and a floor of $387.0 million in Q4 2021.
- Median Shares Outstanding (Weighted Average) over the past 5 years was $388.0 million (2023), compared with a mean of $387.6 million.
- Biggest five-year swings in Shares Outstanding (Weighted Average): increased 17.99% in 2021 and later changed 0.0% in 2022.
- Astrazeneca's Shares Outstanding (Weighted Average) stood at $387.0 million in 2021, then changed by 0.0% to $387.0 million in 2022, then rose by 0.26% to $388.0 million in 2023, then changed by 0.0% to $388.0 million in 2024, then changed by 0.0% to $388.0 million in 2025.
- The last three reported values for Shares Outstanding (Weighted Average) were $388.0 million (Q4 2025), $388.0 million (Q4 2024), and $388.0 million (Q4 2023) per Business Quant data.